Joshua A. Kazam, Director at Nile Therapeutics, Inc. (NLTX), bought 8,200 shares at $1.44 ($9K) on 2008-12-12, disclosed to the SEC on 2008-12-12.
Open-market purchase of $9k NLTX by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history).
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $0.82 | 4,100 | $3K | 36.3% |
| 2 | $1.44 | 4,100 | $6K | 63.7% |
| Total | $1.13 avg | 8,200 | $9K | 100% |
| Filing → |
| EAGL | BUY | 2019-03-01 | $101K | — | Filing → |
| CAPR | BUY | 2015-01-22 | $25K | — | Filing → |
| NLTX | BUY | 2009-03-13 | $383 | — | Filing → |